Table 3 Factors associated with 30 and 90 day mortality in patients without cancer or cancer treatment in the previous 3 months
From: Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma
30 day mortality | 90 day mortality | |||
|---|---|---|---|---|
OR | CI | OR | CI | |
Cancer type (Melanoma vs Other) | 1.38 | 0.69—2.76 | 1.21 | 0.62—2.35 |
Steroids as a COVID-19 treatment, ever | 2.03 | 1.5—2.73 | 2.38 | 1.81—3.14 |
Age, per decade | ||||
Linear | 1.42 | 0.88—2.3 | 1.33 | 0.9—1.97 |
Quadratic | 1.06 | 0.98—1.15 | 1.06 | 0.99—1.13 |
Sex (Male vs Female) | 1.47 | 1.11—1.94 | 1.58 | 1.22—2.04 |
Race (Non-Hispanic White vs Other) | 0.91 | 0.68—1.22 | 0.98 | 0.75—1.28 |
Sunbelt region (yes vs no) | 0.70 | 0.47—1.06 | 0.78 | 0.54—1.12 |
Smoking status (Ever vs Never) | 1.21 | 0.9—1.62 | 1.07 | 0.81—1.4 |
Obesity (yes vs no) | 1.09 | 0.81—1.46 | 0.98 | 0.75—1.28 |
Cardiovascular comorbidities (yes vs no) | 0.97 | 0.72—1.3 | 1.11 | 0.85—1.46 |
Renal disease (yes vs no) | 1.35 | 1—1.82 | 1.41 | 1.06—1.86 |
Pulmonary comorbidities (yes vs no) | 1.35 | 0.99—1.83 | 1.37 | 1.03—1.83 |
Diabetes (yes vs no) | 1.30 | 0.98—1.73 | 1.16 | 0.89—1.51 |
Immunosuppressed (yes vs no) | 1.37 | 0.84—2.25 | 1.70 | 1.1—2.63 |
ECOG status (1 vs 0) | 1.86 | 1.18—2.95 | 1.94 | 1.29—2.93 |
ECOG status (2 + vs 0) | 3.44 | 2.13—5.55 | 4.00 | 2.58—6.18 |
ECOG status (Unknown vs 0) | 1.66 | 1.11—2.47 | 1.52 | 1.06—2.17 |
COVID Diagnosis (2021 vs 2020) | 0.43 | 0.29—0.65 | 0.42 | 0.29—0.61 |